Psoriatic Arthritis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Route of Administration, By Region and Competition, 2020-2030F

Description

Global Psoriatic Arthritis Treatment Market was valued at USD 9.78 Billion in 2024 and is expected to reach USD 13.48 Billion by 2030 with a CAGR of 5.69%. This is driven by advancements in drug development, rising disease awareness, and improvements in diagnostic capabilities. As healthcare systems around the world increasingly recognize the impact of psoriatic arthritis on quality of life and productivity, treatment options are expanding to meet the evolving needs of patients.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 9.78 Billion
Market Size 2030	USD 13.48 Billion
CAGR 2025-2030	5.69%
Fastest Growing Segment	NSAI Ds
Largest Market	North America

Biologic therapies remain the cornerstone of treatment in this market, offering targeted approaches that help control inflammation and prevent joint damage. These therapies are particularly effective for patients with moderate to severe disease and have become widely adopted in both developed and emerging regions. Innovation continues to be a critical factor in shaping the future of this market. Pharmaceutical companies are investing in next-generation therapies that offer improved safety profiles, reduced dosing frequency, and enhanced patient adherence.

Key Market Drivers

Growth in Healthcare Industry

The continued expansion of the global healthcare industry is playing a pivotal role in driving the growth of the psoriatic arthritis treatment market. The global healthcare industry generates annual revenues exceeding USD 4 trillion. The most substantial and profitable segments within the sector are pharmaceuticals and biotechnology, contributing nearly USD 850 billion, followed by medical technology and diagnostics, which generate over USD 400 billion. With increasing investments in healthcare infrastructure, rising patient awareness, and improved access to specialized care, the demand for effective treatment solutions for chronic autoimmune conditions like psoriatic arthritis is steadily rising.

As healthcare systems across both developed and emerging markets evolve, there is greater emphasis on early diagnosis, personalized medicine, and long-term disease management. More than 200,000 Ayushman Arogya Mandirs have been established nationwide to support early diagnosis and treatment. These centers provide millions of citizens with convenient access to screenings for diseases such as cancer, hypertension, and diabetes. This shift is particularly significant for psoriatic arthritis, a complex and progressive condition that requires comprehensive and sustained treatment strategies. The availability of advanced biologics, targeted therapies, and disease-modifying anti-rheumatic drugs (DMARDs) has expanded significantly as part of this healthcare evolution.

Key Market Challenges

High Treatment Costs & Financial Accessibility

One of the foremost challenges confronting the Global Psoriatic Arthritis (PsA) Treatment Market is the high cost associated with advanced therapies, particularly biologics and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs). These innovative treatments, while clinically effective, command significant pricing often reaching tens of thousands of dollars annually per patient. This elevated cost structure poses substantial barriers to patient access, especially in emerging economies and underfunded healthcare systems.

The financial burden not only limits market penetration but also affects patient adherence and long-term treatment outcomes. Payers and insurers are increasingly scrutinizing reimbursement criteria, imposing stringent prior authorization processes that further complicate access. Consequently, patients may experience delays or outright denial of coverage for these essential therapies.

Key Market Trends

Rise of Biologics & Targeted Therapies

The global psoriatic arthritis treatment landscape is witnessing a significant transformation driven by the rapid adoption of biologics and targeted therapies. These advanced treatment modalities have emerged as the cornerstone of disease management, owing to their ability to specifically target underlying inflammatory pathways with enhanced efficacy and safety profiles compared to conventional therapies.

Biologics, including tumor necrosis factor (TNF) inhibitors, interleukin (IL)-17, and IL-23 inhibitors, currently command a substantial share of the market, reflecting their growing acceptance among clinicians and patients alike. In June 2025, Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced that Health Canada has granted a Notice of Compliance (NOC) for Yesafili (aflibercept). Yesafili, a biosimilar to Eylea (aflibercept) injection, is available in vial and prefilled syringe formats at a concentration of 2 mg/0.05 mL. This marks the first approval by Health Canada of a biosimilar to Eylea. Their precision mechanism of action not only improves clinical outcomes but also contributes to better quality of life for patients suffering from psoriatic arthritis.

Key Market Players

AbbVie Inc.
Amgen Inc.
Johnson & Johnson Services, Inc.
Bristol-Myers Squibb Company
Novartis AG
Eli Lilly and Company
Pfizer, Inc.
UCB S.A.

Report Scope

In this report, the Global Psoriatic Arthritis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psoriatic Arthritis Treatment Market, By Drug Class:

NSAIDs
DMARDs
Biologics
Others

Psoriatic Arthritis Treatment Market, By Route of Administration:

Topical
Oral
Injectable

Psoriatic Arthritis Treatment Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psoriatic Arthritis Treatment Market.

Available Customizations:

Global Psoriatic Arthritis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Psoriatic Arthritis Treatment Market

5. Global Psoriatic Arthritis Treatment Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drug Class (NSAIDs, DMARDs, Biologics, Others)
- 5.2.2. By Route of Administration (Topical, Oral, Injectable)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Psoriatic Arthritis Treatment Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drug Class
- 6.2.2. By Route of Administration
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Psoriatic Arthritis Treatment Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drug Class
    - 6.3.1.2.2. By Route of Administration
- 6.3.2. Mexico Psoriatic Arthritis Treatment Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drug Class
    - 6.3.2.2.2. By Route of Administration
- 6.3.3. Canada Psoriatic Arthritis Treatment Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drug Class
    - 6.3.3.2.2. By Route of Administration

7. Europe Psoriatic Arthritis Treatment Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drug Class
- 7.2.2. By Route of Administration
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Psoriatic Arthritis Treatment Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drug Class
    - 7.3.1.2.2. By Route of Administration
- 7.3.2. Germany Psoriatic Arthritis Treatment Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drug Class
    - 7.3.2.2.2. By Route of Administration
- 7.3.3. United Kingdom Psoriatic Arthritis Treatment Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drug Class
    - 7.3.3.2.2. By Route of Administration
- 7.3.4. Italy Psoriatic Arthritis Treatment Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drug Class
    - 7.3.4.2.2. By Route of Administration
- 7.3.5. Spain Psoriatic Arthritis Treatment Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drug Class
    - 7.3.5.2.2. By Route of Administration

8. Asia Pacific Psoriatic Arthritis Treatment Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drug Class
- 8.2.2. By Route of Administration
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Psoriatic Arthritis Treatment Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drug Class
    - 8.3.1.2.2. By Route of Administration
- 8.3.2. India Psoriatic Arthritis Treatment Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drug Class
    - 8.3.2.2.2. By Route of Administration
- 8.3.3. South Korea Psoriatic Arthritis Treatment Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drug Class
    - 8.3.3.2.2. By Route of Administration
- 8.3.4. Japan Psoriatic Arthritis Treatment Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Drug Class
    - 8.3.4.2.2. By Route of Administration
- 8.3.5. Australia Psoriatic Arthritis Treatment Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Drug Class
    - 8.3.5.2.2. By Route of Administration

9. South America Psoriatic Arthritis Treatment Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drug Class
- 9.2.2. By Route of Administration
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Psoriatic Arthritis Treatment Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drug Class
    - 9.3.1.2.2. By Route of Administration
- 9.3.2. Argentina Psoriatic Arthritis Treatment Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drug Class
    - 9.3.2.2.2. By Route of Administration
- 9.3.3. Colombia Psoriatic Arthritis Treatment Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drug Class
    - 9.3.3.2.2. By Route of Administration

10. Middle East and Africa Psoriatic Arthritis Treatment Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drug Class
- 10.2.2. By Route of Administration
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Psoriatic Arthritis Treatment Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drug Class
    - 10.3.1.2.2. By Route of Administration
- 10.3.2. Saudi Arabia Psoriatic Arthritis Treatment Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drug Class
    - 10.3.2.2.2. By Route of Administration
- 10.3.3. UAE Psoriatic Arthritis Treatment Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drug Class
    - 10.3.3.2.2. By Route of Administration

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Global Psoriatic Arthritis Treatment Market: SWOT Analysis

15. Porters Five Forces Analysis

15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products

16. Competitive Landscape

16.1. AbbVie Inc.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (As Reported)
- 16.1.5. Recent Developments
- 16.1.6. Key Personnel Details
- 16.1.7. SWOT Analysis
16.2. Amgen Inc.
16.3. Johnson & Johnson Services, Inc.
16.4. Bristol-Myers Squibb Company
16.5. Novartis AG
16.6. Eli Lilly and Company
16.7. Pfizer, Inc.
16.8. UCB S.A.